An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV).
- Who it may be relevant to
- Registry conditions: Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID). Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Observational Long-term Follow-up Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
Overview
This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as part of the OTL-101-6 study.
Detailed description
The overall aim of this study is to record and evaluate long-term safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA vector, as part of the UCL/A- ADA clinical development program. This will fulfil the requirements for the monitoring of delayed adverse events set by regulatory agencies for subjects treated with gene therapies.
The study will have the following specific objectives:
* To characterize the long-term safety of the gene therapy treatment; * To characterize the long-term clinical efficacy of the gene therapy treatment. Patients who were treated as part of the UCL/A-ADA clinical development program but did not complete the expected follow- up period (e.g. as a consequence of early withdrawal due to safety events) will be included in the LTFU study, subject to their consent and compliance with inclusion and exclusion criteria.
For any patients who completed their expected follow-up period before this study became available, outcome data will be retrospectively collected for the intervening period. From the first LTFU assessment onwards, prospective data will be gathered from the annual standard of care evaluations the patients will receive from the PI or their local healthcare professionals (HCPs).
Each patient, or their legal guardian, will be required to provide informed consent, which will define the objectives of this study, the expected duration of the patient's participation, as well as the data to be collected and the schedule of collection. It is anticipated that data will be collected annually to coincide with standard of care visits.
The study outcomes will be:
* Overall survival (OS) at 15 years of follow-up post treatment with gene therapy; * Event-free survival (EvFS) at 15 years of follow-up post treatment with gene therapy. An "event" will be defined as enzyme replacement therapy (ERT) reinstitution, need for a rescue allogeneic hematopoietic stem cell transplant (HSCT) or further gene therapy treatment; * Use of immunoglobulin replacement therapy (IgRT); * Adverse events (AEs), serious adverse events (SAEs) and safety concerns * Other physical and laboratory parameters
Interventions
- Biological autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Primary outcome measures
- Overall Survival [Time frame: 15 years post-treatment]
- Event-Free Survival [Time frame: 15 years post-treatment]
- Incidence of Adverse Events [Time frame: 15 years post-treatment]
Eligibility criteria
Inclusion criteria
A patient is eligible for enrollment in the study if all of the following criteria are met:
- the patient has been treated with an autologous ex vivo gene therapy product based on the EFS-ADA LV, as part of the OTL-101 clinical development program;
- the patient displays persistent detectable gene marking, as determined by the Investigator;
- the patient or, if applicable, the patient's parent(s)/legal guardian(s), are able and willing to provide informed consent.
Exclusion criteria
- There are no exclusion criteria for participation in this observational LTFU study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
United States · 1 center
- Mattel Children's Hospital UCLA/Ronald Reagan UCLA Medical Center — Los Angeles
United Kingdom · 1 center
- UCL Great Ormond Street Institute of Child Health — London
Publications
- Booth C, Masiuk K, Vazouras K, Fernandes A, Xu-Bayford J, Campo Fernandez B, Roy S, Curio-Penny B, Arnold J, Terrazas D, Reid J, Gilmour KC, Adams S, Alvarez Mediavilla E, Mhaldien L, O'Toole G, Ahmed R, Garabedian E, Malech H, De Ravin SS, Moore TB, De Oliveira S, Pellin D, Lin TY, Dang TT, Cornetta K, Hershfield MS, Hara H, Thrasher AJ, Gaspar HB, Kohn DB. Long-Term Safety and Efficacy of Gene T PMID 41092330
Identifiers
NCT: NCT04049084 · OTL-101-6